Analytical sameness methodology for the evaluation of structural, physicochemical, and biological characteristics of Armlupeg: A pegfilgrastim biosimilar case study.

Autor: Deshmukh A; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Goyal R; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Sundaram K; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Dange K; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Lakhote T; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Niranjan S; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Bharucha J; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Mishra A; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Vats B; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India., Tiwari S; Research and Development, Lupin Limited (Biotechnology Division), Pune, Maharashtra, India.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2023 Aug 09; Vol. 18 (8), pp. e0289745. Date of Electronic Publication: 2023 Aug 09 (Print Publication: 2023).
DOI: 10.1371/journal.pone.0289745
Abstrakt: Pegfilgrastim is administered as an adjunct to chemotherapy to reduce the incidence of febrile neutropenia and associated infectious complications. Lupin's Pegfilgrastim is a proposed biosimilar to the U.S.-referenced Neulasta®. Demonstration of biosimilarity requires extensive physicochemical and functional characterization of the biosimilar, and demonstration of analytical similarity to the reference product, in addition to clinical studies. This work is a case study for demonstrating the analytical similarity of Armlupeg (Lupin's Pegfilgrastim) to Neulasta® with respect to structural and physicochemical attributes using several robust, orthogonal, and state-of-the-art techniques including high-end liquid chromatography, mass spectrometry, and spectroscopy techniques; circular dichroism; differential scanning calorimetry; nuclear magnetic resonance; analytical ultracentrifugation; and micro-flow imaging. Functional similarity was demonstrated using an in vitro cell proliferation assay to measure relative potency and surface plasmon resonance to measure receptor binding kinetics. Furthermore, comparative forced-degradation studies were performed to study the degradation of the products under stress conditions. The product attributes were ranked based on a critical quality attributes risk score according to their potential clinical impact. Based on criticality, all analyses were statistically evaluated to conclude analytical similarity. Lupin's Pegfilgrastim was comparable to Neulasta® as demonstrated via structural, functional, and purity analyses. Lupin's Pegfilgrastim complied with the quality and statistical ranges established using Neulasta®. Both products follow the same degradation pathways under stress conditions as observed in the forced-degradation studies. No new impurity or degradation product was observed in Lupin's Pegfilgrastim. These data conclusively demonstrate the analytical similarity of Lupin's Pegfilgrastim and Neulasta®.
Competing Interests: All authors are paid employees of Lupin Limited and may have stock options. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
(Copyright: © 2023 Deshmukh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje